Phase 2 N=9 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
GIST
Primary: Number of Participants With a Clinical Activity-radiographic Response — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Primary: Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 4; 3; 4 Participants
Phase 2 N=40 Lenalidomide for Patients With Myelofibrosis (MF)
Myelofibrosis
Primary: Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement) — 14 Participants
Phase 2 N=50 Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery
Breast Cancer
Primary: Overall Safety — 12.6 percentage of participants
Phase 2 N=6 Gentamicin for RDEB
Recessive Dystrophic Epidermolysis Bullosa
Primary: Increased Expression of Full-length Type VII Collagen as Assessed by Immunofluorescence — 31.8; 28.4; 65.6 C7 Expression (percent of normal skin)
Phase 2 N=90 A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
Extensive Stage Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 5.88; 5.85 Months — p=0.8072
Phase 2 N=60 Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis
Endometriosis
Primary: Change From Baseline in Individual Biberoglu Behrman Symptom Severity Scale (BBSS) Score for Dysmenorrhea — 12.6; 10.8; 11.1; -3.95 score on a scale per 28-day period…
Phase 2 N=46 Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma
Asthma
Primary: Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose — 0.421; 0.488; 0.548; 0.586 Liter
Phase 2 N=99 A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Overall Response Rate (ORR) — 13.0; 4.3 Percentage of participants
Phase 2 N=129 Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
End-Stage Renal Disease
Primary: Safety - Number of Participants With Serum Potassium >6.5 mEq/L — 9; 4; 4; 8 Participants
Phase 2 N=12 An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Number of Participants With Adverse Events as Assessed by CTCAE Version 4.03 — 10; 10; 11; 11 participants
Phase 2 N=305 A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment — 329; 306; 300; 328 meter — p=0.5183
Phase 2 N=46 Prevention of Vitamin D Deficiency Following Pediatric CHD Surgery: a Phase II Dose Evaluation Randomized Controlled Trial Comparing Usual Care With a High Dose Pre-operative Supplementation Regimen Based on the Institute of Medicine Daily Upper Tolerable Intake Level
Vitamin D Deficiency · Thoracic Surgery · Pediatric Disorders
Primary: Blood 25 Hydroxyvitamin D (25OHD) Concentrations — 34.8; 52.0 nmol/L
Phase 2 N=20 Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Cmax of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate (Single Dose). — 45.82; 3149; 38.82; 4.786 pg/mL
Phase 2 N=76 Evaluation of the 2005 AMS (American Medical System) IPP (Inflatable Penile Prosthesis)
Erectile Dysfunction
Primary: Ease of Locating the Inflation Pump Bulb — 63 Participants who easily located pumpbulb